Nurix Therapeutics, Inc. (NRIX) Stock Analysis
A live, multi-source view of Nurix Therapeutics, Inc. (NRIX): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc.
Sector: Healthcare · Industry: Biotechnology · United States · 317 employees · nurixtx.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Nurix Therapeutics, Inc. (NRIX) had a market capitalization of $2.71B (forward -24.5) and a beta of 1.80; the shares traded in a 52-week range of $8.20 – $28.23 (161.0% over the year).
- Market cap
- $2.71B
- Enterprise value
- $2.33B
- Forward P/E
- -24.5
- Price / book
- 6.73
- EPS (trailing)
- $-3.58
- EPS (forward)
- $-1.07
- Payout ratio
- 0.0%
- 52-week range
- $8.20 – $28.23
- 52-week change
- 161.0%
- Beta
- 1.80
- Average volume
- 2.0M
- Shares outstanding
- 103.8M
- Short % of float
- 17.52%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Nurix Therapeutics, Inc. (NRIX) last closed at $25.81 (the last completed close before that scan).
Technicals at the scan: RSI 51 (neutral territory), price -2.6% versus its 20-day average, 20-day versus 50-day average spread +5.9%, MACD histogram -0.21.
Sentiment inputs: 67% of recent Finnhub-scored headlines read bullish; StockTwits 100% bullish; analyst consensus score 82/100.
Next scheduled company event: in 27 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of NRIX; corporate insiders filed 0 buys and 12 sells (3 distinct filers, latest disclosure 2026-09-02). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Gwenn Hansen (0B/5S), Christine Ring (0B/4S), Houte Hans Van (0B/3S). Who is trading what
RapidTradeView pick record
NRIX has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Nurix Therapeutics, Inc. (NRIX) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell NRIX.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.